ArticleOncotarget2016
An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Predictors of Recurrence After Surgery in Patients with Stage I Non-Small Cell Lung Cancer.Cancers · 2026Article
- Article
- 5-mRNA-based prognostic signature of survival in lung adenocarcinoma.World journal of clinical oncology · 2023Article
- Review
- A nine-gene signature to improve prognosis prediction of colon carcinoma.Cell cycle (Georgetown, Tex.) · 2021Article
- Article
- Pan-Cancer Transcriptional Models Predicting Chemosensitivity in Human Tumors.Cancer informatics · 2021Article
- A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer.Molecular therapy oncolytics · 2020Article
- Denoising Autoencoder, A Deep Learning Algorithm, Aids the Identification of A Novel Molecular Signature of Lung Adenocarcinoma.Genomics, proteomics & bioinformatics · 2020Article
- Article
- Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer.BioMed research international · 2020Article
- Identification of Prognosis-Related Genes in Bladder Cancer Microenvironment across TCGA Database.BioMed research international · 2020Article
- A Novel Six-Gene Signature for Prognosis Prediction in Ovarian Cancer.Frontiers in genetics · 2020Article
- A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer.BioMed research international · 2020Article
- Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis.Oncotarget · 2019Article
- A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors.Oncotarget · 2019Article
- Comparative genomic analysis of collagen gene diversity.3 Biotech · 2019Article
- DNA hypomethylation-related overexpression of SFN, GORASP2 and ZYG11A is a novel prognostic biomarker for early stage lung adenocarcinoma.Oncotarget · 2019Article
- A Six-Gene Signature Predicts Survival of Adenocarcinoma Type of Non-Small-Cell Lung Cancer Patients: A Comprehensive Study Based on Integrated Analysis and Weighted Gene Coexpression Network.BioMed research international · 2019Article
- A Pathway-Based Strategy to Identify Biomarkers for Lung Cancer Diagnosis and Prognosis.Evolutionary bioinformatics online · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of a potential gene signature for improved diagnosis in non-small cell lung cancer (NSCLC) patient is necessary. Here, we aim to establish and validate the prognostic efficacy of a gene set that can predict prognosis and benefits of adjuvant chemotherapy (ACT) in NSCLC patients from various ethnicities. An 8-gene signature was calculated from the gene expression of 181 patients using univariate Cox proportional hazard regression analysis. The prognostic value of the signature was robustly validated in 1,477 patients from five microarray independent data sets and one RNA-seq data set. The 8-gene signature was identified as an independent predictor of patient survival in the presence of clinical parameters in univariate and multivariate analyses [hazard ratio (HR): 2.84, 95% confidence interval CI (1.74-4.65), p=3.06e-05, [HR] 2.62, 95% CI (1.51-4.53), p=0.001], respectively. Subset analysis demonstrated that the 8-gene signature could identify high-risk patients in stage II-III with improved survival from ACT [(HR) 1.47, 95% CI (1.01-2.14), p=0.044]. The 8-gene signature also stratified risk groups in EGFR-mutated and wild-type patients. In conclusion, the 8-gene signature is a strong and independent predictor that can significantly stratify patients into low- and high-risk groups. Our gene signature also has the potential to predict patients in stage II-III that are likely to benefit from ACT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.